{"id":"W4407095407","doi":"10.1016/s1470-2045(24)00682-x","title":"Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"Janssen Alzheimer Immunotherapy Research And Development; Janssen Research and Development","keywords":"Ibrutinib; Venetoclax; Mantle cell lymphoma; Medicine; Placebo; Refractory (planetary science); Internal medicine; Oncology; Double blind; Phases of clinical research; Lymphoma; Clinical trial; Leukemia; Pathology; Chronic lymphocytic leukemia","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001491434,0.001775598,0.003230734,0.0004915841,0.000422442,0.00119277,0.00100037,0.001653593,0.005817516],"category_scores_gemma":[0.001135474,0.0006595046,0.001822369,0.0004557734,0.001113071,0.0009901172,0.00038431,0.002975042,0.001066928],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006420864,"about_ca_system_score_gemma":0.0007687829,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001134572,"about_ca_topic_score_gemma":0.002479403,"domain_scores_codex":[0.9995627,0.0002130004,0.00001910338,0.00007417938,0.00003460799,0.00009650247],"domain_scores_gemma":[0.9994851,0.0001423158,0.0001020852,0.00004502158,0.00002541256,0.0002000184],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9712659,0.005340309,0.0003046869,0.0009212582,0.000965578,0.0000367739,0.00005164215,0.0002776039,0.003417027,0.0001254466,0.0007701152,0.01652373],"study_design_scores_gemma":[0.9499043,0.04771403,0.001095585,0.00003220106,0.0003222678,0.00002362758,0.00001919294,0.000170696,0.0001935606,0.00008070162,0.0004315665,0.00001219306],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9819474,0.01097388,0.000671845,0.0005425779,0.000738605,0.001759084,0.0008806602,0.000191917,0.002293931],"genre_scores_gemma":[0.98432,0.005835246,0.001393784,0.001200392,0.00056515,0.002021671,0.000933548,0.00003894313,0.003691352],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005817516,"threshold_uncertainty_score":0.01946151,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06933435470979207,"score_gpt":0.4133611366597585,"score_spread":0.3440267819499665,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}